Understanding how gastric emptying affects blood sugar in type 1 diabetes
The Effect of Gastric Emptying on Blood Glucose Profile of Type 1 Diabetes Mellitus and Its Therapeutic Strategies
NA · Nanjing First Hospital, Nanjing Medical University · NCT06173934
This study is testing how the speed of stomach emptying affects blood sugar levels in people with type 1 diabetes to help personalize their insulin treatment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | N/A to 70 Years |
| Sex | All |
| Sponsor | Nanjing First Hospital, Nanjing Medical University (other) |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT06173934 on ClinicalTrials.gov |
What this trial studies
This study aims to establish a cohort of patients with type 1 diabetes to investigate the relationship between gastric emptying and blood glucose levels. Participants will undergo a 14-day continuous glucose monitoring period while maintaining a stable diet. Based on the results of gastric emptying tests, insulin injection timing will be adjusted for different groups of patients to optimize blood glucose control. The study seeks to provide insights into personalized insulin management for individuals with type 1 diabetes.
Who should consider this trial
Good fit: Ideal candidates are individuals with type 1 diabetes under 70 years old, with HbA1c levels between 7% and 9% and no acute complications.
Not a fit: Patients with severe gastrointestinal issues or those who have recently used medications affecting gastrointestinal function may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved blood glucose control and reduced fluctuations for patients with type 1 diabetes.
How similar studies have performed: While the specific approach of adjusting insulin timing based on gastric emptying is novel, similar studies have shown promise in optimizing diabetes management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1.Volunteer and sign subject informed consent prior to the trial. 2.Patients with type 1 diabetes, aged less than 70 years, 7%≤HbA1c≤9.0%. 3.There were no acute complications such as diabetic ketoacidosis and diabetic hypertonic syndrome. 4.Subjects were able and willing to undergo 14-day scanning blood glucose monitoring, diet and exercise routine. Exclusion Criteria: * 1.Patients with severe gastrointestinal symptoms, history of gastrointestinal disease, surgical history, or impaired liver and kidney function. 2.Patients who have used drugs that affect gastrointestinal function or appetite in the last week. 3.History of drug abuse and alcohol dependence within the past 5 years. 4.Systemic hormone therapy was used in the last three months. 5.Patients with poor compliance, irregular diet and exercise. 6.Patients with infection and stress within four weeks. 7.Patients who could not tolerate 14-day scanning blood glucose monitoring. 8.Patients who are pregnant, nursing or intending to become pregnant. 9.Any other obvious condition or comorbidities determined by the investigator: such as serious cardiopulmonary disease, endocrine disease, neurological, neoplastic, other pancreatic disease, history of mental illness.
Where this trial is running
Nanjing, Jiangsu
- Nanjing First Hospital, Nanjing Medical University — Nanjing, Jiangsu, China (RECRUITING)
Study contacts
- Principal investigator: Jianhua Ma — Nanjing Medical University affiliated Nanjing First Hospital
- Study coordinator: Yong Luo
- Email: luoyong132270@sina.com
- Phone: +86 18951670850
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Diabetes